Table 1: Visual acuity increase from baseline at 180 days follow-up
Group 1: intravitreal injection of etamsylate followed by sham-treatment. Group 2: sham-treatment followed by etamsylate intravitreal injection. Data are expressed as mean±SD of the difference from baseline in the number of letters read in the ETDRS optotype. Patients in etamsylate/sham group were intravitreally injected with 12.5 mg etamsylate and sham-operated at 90 days after injection. Patients in sham/etamsylate group were sham-operated at day 0 and injected with etamsylate 12.5 mg at day 90. p was determined by linear regression mixed model with baseline BCVA included as covariate.